Dr. Tang holds an MD degree from the Wannan Medical College, Wuhu, China; a Master degree in Immunology from Shanghai Medical College Fudan University; and a PhD degree in Microbiology and Immunology from the University of Arizona. Following medical school, Dr. Tang practiced medicine as a radiologist for 2 years in Huangshan City People’s Hospital, Huangshan, Anhui province, China. After receiving his Master degree, he was appointed as a lecturer for 4 years in the Department of Immunology at Shanghai Medical College, Fudan University. After obtaining his PhD degree from the University of Arizona, Dr. Tang joined as a postdoctoral fellow Dr. Vipin Kumar’s research laboratory at Torrey Pines Institute for Molecular Studies in San Diego, California, where he remained for 4 years. Later he accepted a Research Associate position in the laboratory of Dr. Harvey Cantor at the Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts. After 3.5 years at Harvard, he became a faculty member at the University of Texas, El Paso, Texas where he stayed for 3 years before joining as an Associate Research Professor, for a total of 6 years, the Division of Regenerative Medicine, Department of Medicine, School of Medicine at Loma Linda University in California. Dr. Tang joined the Long Island University College of Veterinary Medicine in September 2019. Dr. Tang has considerable teaching experience. He has taught undergraduate and graduate students, medical students, and other professional students. He has developed syllabi and directed courses mainly in immunology. During his interactions with students, Dr. Tang strives to convey his passion for the discipline and to promote a learning environment that fosters student participation and small group discussion. Dr. Tang often emphasizes essential basic science concepts into clinically relevant scenarios that can be easily understood by students with different levels of knowledge. Dr. Tang’s research interests include regulatory T (Treg) cells and the role of immune system in tissue repair. In the area of Treg cells, he is interested in the roles of 1,25(OH)2D (i.e. the active vitamin D metabolite) and retinoic acid (RA, i.e. the active vitamin A metabolite) in the induction of Treg cells and in the treatment of immune-mediated diseases through tissue-specific delivery of these two molecules. In addition, he is interested in the immune regulatory mechanisms of Qa-1(HLA-E in human)-restricted CD8 T cells. In the area of tissue repair, he is interested in the role of the immune system in stem cells. Such role may include stem cell recruitment, priming, and differentiation. The ultimate goals of the above studies are to develop novel therapies for diseases with improved safety and efficacy. Dr. Tang has consistently received extramural funding for his research from National Institute of Health (NIH), Department of Defense (DoD), and the National Multiple Sclerosis Society (NMSS).
Dr. Martin has been a full professor at Stanford University for several years and is affiliated with several programs, including the Stanford Cancer Research Institute. He has contributed to many areas of biological research, e.g., bacterial infections and their treatment; discovery of new drugs and therapeutic enzymes and their improvement. He has pioneered mRNA-based gene delivery specifically to cancer using exosomes promising cure without side-effects – this approach is applicable to gene delivery-mediated treatment also of other diseases. He did his Ph. D. at UCLA, spent some years in the Netherlands (State University of Groningen), where he directed a research group, before joining Stanford. He is a recipient of numerous awards and honors.
Ken H. Young is a Professor at The University of Texas MD Anderson Cancer Center in the Department of Hematopathology. Young completed his MD at Zhejiang University School of Medicine, China in 1984. Dr. Ken primary study of genomic alterations is on TP53 tumor suppressor pathway. His secondary focus is on Myc oncogene. Weblink to MD Anderson SciVal research profile and PubMed list of publication is attached. Ken research team performs several types of hematologic malignancies, with special emphasis on pathogenesis of malignant lymphomas, especially diffuse large B-cell lymphoma (DLBCL). DLBCL is an aggressive B-cell lymphoma which brings together the worst characteristics of both high-grade features and aggressive biology. The disease is incurable in nearly 40% patients. Ken has published over 134 articles in different journals. Dr. Ken has worked as committee member at American Board of Pathology, Anatomic and Clinical Pathology, and the American Board of Hematology. Currently, Dr. Ken is Vice-Chair for the IRG Pilot Grant Review Committee at The University of Texas MD Anderson Cancer Center, Houston.
Dr. Whiteside is a professor of Pathology, Immunology, and Otolaryngology and a member of the University of Pittsburgh Cancer Institute. Dr. Whiteside is a clinical immunologist with many years of experience in evaluating human immune-mediated diseases. Dr. Whiteside is served as Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the UPMC Hillman Cancer Center for 25 years and am currently serving as Interim Director. The IMCPL offers a broad spectrum of immunodiagnostic and monitoring assays for testing of patients with cancer. The laboratory also serves as a cGMP facility which generates cellular products for immunotherapy of patients with cancer and HIV.
DR. ALAIN L. FYMAT is a medical-physical scientist and an educator. He is the current President/ CEO and Institute Professor at the International Institute of Medicine & Science with a previous appointment as Executive Vice President/Chief Operating Officer and Professor at the Weil Institute of Critical Care Medicine, California, U.S.A. He was formerly Professor of Radiology, Radiological Sciences, Radiation Oncology, Critical Care Medicine, and Physics at several U.S. and European Universities. Earlier, he was Deputy Director (Western Region) of the U.S. Department of Veterans Affairs (Office of Research Oversight). At the Loma Linda Veterans Affairs Medical Center, he was Scientific Director of Radiology, Director of the Magnetic Resonance Imaging Center and, for a time, Acting Chair of Radiology. Previously, he was Director of the Division of Biomedical and Biobehavioral Research at the University of California at Los Angeles/Drew University of Medicine and Science. He was also Scientific Advisor to the U.S. National Academy of Sciences, National Research Council, for its postdoctoral programs tenable at the California Institute of Technology and Member of the Advisory Group for Research & Development, North Atlantic Treaty Organization (NATO). He is Health Advisor to the American Heart & Stroke Association, Coachella Valley Division, California. He is a frequent Keynote Speaker and Organizing Committee member at several international scientific/medical conferences. He has lectured extensively in the U.S.A, Canada, Europe, Asia, and Africa. He has publishedin excess of 475 scholarly scientific publications and books. He is also Editor-in-Chief, Honorable Editor or Editor of numerous medical/scientific Journals to which he regularly contributes. He is a member of the New York Academy of Sciences and the European Union Academy of Sciences, a Board member of several institutions, and a reviewer for the prestigious UNESCO Newton Prize, United Kingdom National Commission for UNESCO. Dr. Fymat's current research interests are focused on neurodegenerative diseases (Alzheimer's, Parkinson's, dementias, epilepsy, and others), oncology (glioblastoma), epigenetics & ecogenetics, and nanomedicine & nanobiotechnology. These are represented in part in his latest books: “From the Heart to the Brain: My collected works in medical science research (2016-2018)”, “Alzhei ...Who? Demystifying the disease and what you can do about it”, “The Odyssey of Humanity's Diseases: Epigenetic and ecogenetic modulations from ancestry through inheritance, environment, culture and behavior” Volumes 1, 2, and 3, “Parkin..ss..oo..nn: Elucidating the disease and what you can do about it”, “Lyme disease: The great invader, evader, and imitator”, and “Dementia: Fending-off the menacing disease... and what you can do about it”.
Dr. McConkey is an Associate Professor and group leader of Heredity, Disease & Development at the University of Leeds. He has contributed to delineating host-pathogen interactions and identified numerous antimalarial drug targets. His investigations of CNS infection uncovered modulation of the central regulator of neuroinflammation. Current research explores the role of exosomes in suppressing noradrenergic signalling responsible for neural cytokine regulation. As a postdoc and senior fellow at NIH, he defined antigenic diversity in the malaria vaccine and generated auxotrophic parasites as potential of attenuated vaccines. He has been on panels for UK, US, French, Israeli, and Swiss research councils and is currently serving on the UK COVID-19 Therapeutic Advisory team.
Andreia Rezende is from São Luís do Maranhão, but spent her childhood in the south of the state, in the city of Balsas. Bachelor of Dentistry from the Federal University of Maranhão - UFMA, she is the mother of the twins Tulio and Heitor and wife of former state deputy Stenio Rezende, who has a solid and respected political career throughout Maranhão. State deputy elected for the quadrennium from 2019 to 2022.
Dr. Hiroshi Shiku is a professor in the Department of Personalized Cancer Immunotherapy at Mie University. He has been working on analysis of molecular characteristics of tumor antigens and T cells in anti-tumor immune responses, and also development of immunotherapeutic approaches for cancer. He has developed a novel protein-based cancer vaccine with unique antigen delivery system of cholesterol-bearing hydrophobized polysaccharides (CHP). He more recently has been also developing adoptive cell therapy with TCR gene-transduced T cells aiming at developing comprehensive cancer immunotherapy.
Jorge Kalil is Professor of Clinical Immunology and Allergy, Director, Immunology Laboratory, Heart Institute, School of Medicine, University of São Paulo; Adjunct Professor at the GWU, USA; Coordinator, iii-Institute for Investigative Immunology; Former Director, Butantan Institute; Past President, International Union of Immunological Societies. Graduated in Medicine, Doctor of Science in Human Biology, University of Paris VII, in Jean Dausset’s laboratory (Nobel Prize 1980 for HLA). He was Visiting Professor, Stanford School of Medicine, and International Scholar, Howard Hughes Medical Institute. He studies the mechanisms of immune recognition and distinction of self and no self, with over 550 publications (ISI) and several patents. He is member of the Brazilian Academy of Sciences, Grand Cross of the Brazilian National Order of Scientific Merit, Chevalier of the National Order of Merit of France, Doctor Honoris causa by Sorbonne Universités and Fellow of the Royal College of Physicians. He represents Brazil in the ICGEB.
Dr. Jianwei Zhu spent his post-doctoral research at MIT and Harvard Medical School to develop his expertise for the career in biopharmaceutical development. Since 1997, Jianwei played technical leadership role in the Biopharmaceutical Development Program at Frederick National Laboratory for Cancer Research for developing ~38 biopharmaceuticals mainly for phase I to III clinical trials. His expertise in clinical development of biopharmaceuticals has been provided through consultation services to a number Institutes including International Vaccine Institute (United Nation found) and NIH as well as to biopharmaceutical companies internationally. He recently has been awarded as Distinguished Expert by the "Thousand Expert Plan" of China and pointed as “ZhiYuan” Chair Professor, and Director of the Engineering Research Center of Cell & Therapeutic Antibody, Ministry of Education, at Shanghai JiaoTong University.
Ahmed Hegazi is currently a Professor of Microbiology and Immunology in the National Research Center, Egypt. Prof. Hegazi received his master’s degree in 1979 and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 222 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA).